How much profit has Idorsia made this year?
Idorsia has made -307.85 M CHF this year.
Idorsia Net Income 2024
Idorsia Net Income
-307.85 M CHF
Ticker
IDIA.SW
ISIN
CH0363463438
WKN
A2DTEB
In 2024, Idorsia's profit amounted to -307.85 M CHF, a 3.33% increase from the -297.92 M CHF profit recorded in the previous year.
The Idorsia Net Income history
| YEAR | NET INCOME (undefined CHF) |
|---|---|
| 2028e | - |
| 2027e | - |
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Idorsia Revenue, EBIT, Net Income CH0363463438 · A2DTEB
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Idorsia, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Idorsia from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Idorsia’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Idorsia. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Idorsia’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Idorsia’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Idorsia’s growth potential.
Idorsia Revenue, EBIT and net profit per share
| Date | Idorsia Revenue | Idorsia EBIT | Idorsia Net Income |
|---|---|---|---|
| 2028e | 533.03 M CHF | 0 CHF | 0 CHF |
| 2027e | 404.29 M CHF | -84.38 M CHF | -18.57 M CHF |
| 2026e | 415.75 M CHF | -52.02 M CHF | -80.82 M CHF |
| 2025e | 218.38 M CHF | -329.03 M CHF | -234.38 M CHF |
| 2024e | 98.7 M CHF | -371.64 M CHF | -307.85 M CHF |
| 2023 | 152.39 M CHF | -543.05 M CHF | -297.92 M CHF |
| 2022 | 97.1 M CHF | -802.97 M CHF | -827.9 M CHF |
| 2021 | 35.35 M CHF | -613 M CHF | -634.6 M CHF |
| 2020 | 71.76 M CHF | -410.58 M CHF | -444.79 M CHF |
| 2019 | 23.82 M CHF | -482.42 M CHF | -493.61 M CHF |
| 2018 | 60.62 M CHF | -371.08 M CHF | -386.39 M CHF |
| 2017 | 158.09 M CHF | -7.89 M CHF | -14.27 M CHF |
| 2016 | 0 CHF | -322.82 M CHF | -335.14 M CHF |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2016 | 0 CHF | -322.82 M CHF | -335.14 M CHF |
| 2017 | 158.09 M CHF | -7.89 M CHF | -14.27 M CHF |
| 2018 | 60.62 M CHF | -371.08 M CHF | -386.39 M CHF |
| 2019 | 23.82 M CHF | -482.42 M CHF | -493.61 M CHF |
| 2020 | 71.76 M CHF | -410.58 M CHF | -444.79 M CHF |
| 2021 | 35.35 M CHF | -613 M CHF | -634.6 M CHF |
| 2022 | 97.1 M CHF | -802.97 M CHF | -827.9 M CHF |
| 2023 | 152.39 M CHF | -543.05 M CHF | -297.92 M CHF |
| 2024e | 98.7 M CHF | -371.64 M CHF | -307.85 M CHF |
| 2025e | 218.38 M CHF | -329.03 M CHF | -234.38 M CHF |
| 2026e | 415.75 M CHF | -52.02 M CHF | -80.82 M CHF |
| 2027e | 404.29 M CHF | -84.38 M CHF | -18.57 M CHF |
| 2028e | 533.03 M CHF | 0 CHF | 0 CHF |
Idorsia stock margins CH0363463438 · A2DTEB
The Idorsia margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Idorsia. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Idorsia.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Idorsia's sales revenue. A higher gross margin percentage indicates that the Idorsia retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Idorsia's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Idorsia's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Idorsia's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Idorsia. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Idorsia's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Idorsia Margin History
| Idorsia Gross margin | Idorsia Profit margin | Idorsia EBIT margin | Idorsia Profit margin |
|---|---|---|---|
| 2028e | 95.31 % | 0 % | 0 % |
| 2027e | 95.31 % | -20.87 % | -4.59 % |
| 2026e | 95.31 % | -12.51 % | -19.44 % |
| 2025e | 95.31 % | -150.67 % | -107.33 % |
| 2024e | 95.31 % | -376.54 % | -311.91 % |
| 2023 | 95.31 % | -356.37 % | -195.5 % |
| 2022 | 93.55 % | -826.93 % | -852.6 % |
| 2021 | 95.31 % | -1,734.15 % | -1,795.23 % |
| 2020 | 95.31 % | -572.18 % | -619.85 % |
| 2019 | 95.31 % | -2,025.36 % | -2,072.33 % |
| 2018 | 95.31 % | -612.15 % | -637.42 % |
| 2017 | 95.31 % | -4.99 % | -9.03 % |
| 2016 | 95.31 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2016 | 95.31 % | 0 % | 0 % |
| 2017 | 95.31 % | -4.99 % | -9.03 % |
| 2018 | 95.31 % | -612.15 % | -637.42 % |
| 2019 | 95.31 % | -2,025.36 % | -2,072.33 % |
| 2020 | 95.31 % | -572.18 % | -619.85 % |
| 2021 | 95.31 % | -1,734.15 % | -1,795.23 % |
| 2022 | 93.55 % | -826.93 % | -852.6 % |
| 2023 | 95.31 % | -356.37 % | -195.5 % |
| 2024e | 95.31 % | -376.54 % | -311.91 % |
| 2025e | 95.31 % | -150.67 % | -107.33 % |
| 2026e | 95.31 % | -12.51 % | -19.44 % |
| 2027e | 95.31 % | -20.87 % | -4.59 % |
| 2028e | 95.31 % | 0 % | 0 % |
Idorsia Aktienanalyse
What does Idorsia do?
Idorsia Ltd is a biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for patients. The company is headquartered in Switzerland and was founded in 2017 after being spun off from Actelion Ltd. Idorsia was formed by a team of experienced scientists and developers who are known in the industry for their skills and passion for researching new therapies. The company is divided into five main business areas: cardiovascular and respiratory, CNS, immunology, pain, and oncology. Through its research and development activities, Idorsia aims to address medical needs in various areas. The company's innovative therapy approaches have already shown promise and garnered significant attention in the industry. Idorsia receives support from investors and partners. Idorsia's business model is based on an extensive portfolio of already patented and yet-to-be-patented drugs. The company strives to continually optimize and expand its developments within the industry to ultimately treat patients worldwide with its therapies. It collaborates closely with various partners from the biotechnology, pharmaceutical, and other industries to bring products to market and translate scientific knowledge into clinical practice. In the cardiovascular and respiratory field, Idorsia focuses on developing therapies for pulmonary hypertension as well as severe, acute, and chronic cardiovascular diseases. The company's goal is to reduce interventions and interventions for the treatment of these diseases through new treatment options, thus effectively and sustainably improving patients' quality of life. In neurology, Idorsia is involved in research and development of new therapies for disorders of the central nervous system. Here, the company targets the treatment of severe conditions such as epilepsy, sleep disorders, Alzheimer's, and Parkinson's. The research and development activities are carried out in close collaboration with academic research centers and clinics and have already shown success in developing new therapies. In the field of immunology, the company focuses on the development of biological therapies to support the body's immune system in fighting tumors and other severe diseases. Idorsia also focuses on the advancement of personalized medicines tailored to individual patients. In terms of pain, the company focuses on developing therapies that can effectively reduce pain without affecting the patient's perception and quality of life. Idorsia is working on the development of treatment methods that span longer periods and thus serve as an effective alternative to conventional pain therapies. One of the main products introduced by Idorsia is the drug Daridorexant. The drug is a highly selective receptor antagonist developed for the treatment of sleep disorders and other sleep-related conditions. In addition, Idorsia is working on the development of new therapies in the neurology and cardiovascular disease fields. Overall, Idorsia is dedicated to providing patients with valuable and innovative treatment options and, thereby, improving their quality of life. The company relies on scientific research and continuous improvement of its products and services to ensure long-term success in the industry. Idorsia ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Idorsia's Profit Margins
The profit margins of Idorsia represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Idorsia's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Idorsia's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Idorsia's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Idorsia’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Idorsia stock
How has the profit developed compared to last year?
The profit has increased by 3.33% compared to last year increased
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Idorsia publish its earnings?
Idorsia publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Idorsia?
The profits of Idorsia are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Idorsia?
You can learn more about the earnings of Idorsia by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Idorsia pay?
Over the past 12 months, Idorsia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Idorsia is expected to pay a dividend of 0 CHF.
What is the dividend yield of Idorsia?
The current dividend yield of Idorsia is .
When does Idorsia pay dividends?
Idorsia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Idorsia?
Idorsia paid dividends every year for the past 0 years.
What is the dividend of Idorsia?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Idorsia located?
Idorsia is assigned to the 'Health' sector.
Wann musste ich die Aktien von Idorsia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Idorsia from 9/26/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.
When did Idorsia pay the last dividend?
The last dividend was paid out on 9/26/2024.
What was the dividend of Idorsia in the year 2023?
In the year 2023, Idorsia distributed 0 CHF as dividends.
In which currency does Idorsia pay out the dividend?
The dividends of Idorsia are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Idorsia
Our stock analysis for Idorsia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Idorsia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
